RNAi-mediated CCR5 silencing by LFA-1-targeted nanoparticles prevents HIV infection in BLT mice

Molecular Therapy

Volumn 18, Issue 2, 2010, Pages 370-376

  Kim, Sang Soo ^a,b   Peer, Dan ^b,c,d   Kumar, Priti ^e   Subramanya, Sandesh ^a,b   Wu, Huaquan ^a,b   Asthana, Deshratan ^f   Habiro, Katsuyoshi ^g   Yang, Yong Guang ^g   Manjunath, N ^a,b   Shimaoka, Motomu ^b,c   Shankar, Premlata ^a,b  

^a Paul L Foster School of Medicine   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d TEL AVIV UNIVERSITY   (Israel)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; CD14 ANTIGEN; CD19 ANTIGEN; CHEMOKINE RECEPTOR CCR5; LIPOSOME; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; NANOPARTICLE; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DOSE RESPONSE; GENE SILENCING; GENE THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VIVO STUDY; LYMPHOCYTE ACTIVATION; MACROPHAGE; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PROTEIN TARGETING; RNA INTERFERENCE; T CELL DEPLETION; T LYMPHOCYTE; VIRUS LOAD;

ANIMALS; GENE SILENCING; HIV INFECTIONS; LEUKOCYTES; LIPOSOMES; LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-1; MICE; NANOPARTICLES; RECEPTORS, CCR5; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA, SMALL INTERFERING;

HUMAN IMMUNODEFICIENCY VIRUS; MUS;

EID: 76349095131     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2009.271     Document Type: Article

References (31)

1. Rossi, JJ (2006). RNAi as a treatment for HIV-1 infection. Biotechniques (suppl.): 25-29.
2. Lee, SK, Dykxhoorn, DM, Kumar, P, Ranjbar, S, Song, E, Maliszewski, LE, et al. (2005). Lentiviral delivery of short hairpin RNAs protects CD4 T cells from multiple clades and primary isolates of HIV. Blood 106: 818-826.
3. Kumar, P, Ban, HS, Kim, SS, Wu, H, Pearson, T, Greiner, DL, et al. (2008). T cell-specifc siRNA delivery suppresses HIV-1 infection in humanized mice. Cell 134: 577-586.
4. Novina, CD, Murray, MF, Dykxhoorn, DM, Beresford, PJ, Riess, J, Lee, SK, et al. (2002). siRNA-directed inhibition of HIV-1 infection. Nat Med 8: 681-686.
5. Song, E, Zhu, P, Lee, SK, Chowdhury, D, Kussman, S, Dykxhoorn, DM, et al. (2005). Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol 23: 709-717.
6. Peer, D, Zhu, P, Carman, CV, Lieberman, J and Shimaoka, M (2007). Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1. Proc Natl Acad Sci USA 104: 4095-4100.
7. Peer, D, Park, EJ, Morishita, Y, Carman, CV and Shimaoka, M (2008). Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-infammatory target. Science 319: 627-630.
8. Ostrowski, MA, Chun, TW, Justement, SJ, Motola, I, Spinelli, MA, Adelsberger, J, et al. (1999). Both memory and CD45RA+/CD62L+ naive CD4(+) T cells are infected in human immunodefciency virus type 1-infected individuals. J Virol 73: 6430-6435.
9. Marques, JT and Williams, BR (2005). Activation of the mammalian immune system by siRNAs. Nat Biotechnol 23: 1399-1405.
10. Judge, AD, Sood, V, Shaw, JR, Fang, D, McClintock, K and MacLachlan, I (2005). Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol 23: 457-462.
11. Peer, D and Margalit, R (2004). Loading mitomycin C inside long circulating hyaluronan targeted nano-liposomes increases its antitumor activity in three mice tumor models. Int J Cancer 108: 780-789.
12. Nakata, H, Maeda, K, Miyakawa, T, Shibayama, S, Matsuo, M, Takaoka, Y, et al. (2005). Potent anti-R5 human immunodefciency virus type 1 effects of a CCR5 antagonist, AK602/ONO4128/GW873140, in a novel human peripheral blood mononuclear cell nonobese diabetic-SCID, interleukin-2 receptor gamma-chain-knocked-out AIDS mouse model. J Virol 79: 2087-2096.
13. Fais, S, Lapenta, C, Santini, SM, Spada, M, Parlato, S, Logozzi, M, et al. (1999). Human immunodefciency virus type 1 strains R5 and X4 induce different pathogenic effects in hu-PBL-SCID mice, depending on the state of activation/ differentiation of human target cells at the time of primary infection. J Virol 73: 6453-6459.
14. Berges, BK, Wheat, WH, Palmer, BE, Connick, E and Akkina, R (2006). HIV-1 infection and CD4 T cell depletion in the humanized Rag2-/-gamma c-/-(RAG-hu) mouse model. Retrovirology 3: 76.
15. Jacovina, A and New, M (2008). Chemokine (C-C motif) receptor 5 entry inhibitors: new class of drugs for acquired immune defciency syndrome. Mt Sinai J Med 75: 297-298.
16. Qian, K, Morris-Natschke, SL and Lee, KH (2009). HIV entry inhibitors and their potential in HIV therapy. Med Res Rev 29: 369-393.
17. Gorantla, S, Sneller, H, Walters, L, Sharp, JG, Pirruccello, SJ, West, JT, et al. (2007). Human immunodefciency virus type 1 pathobiology studied in humanized BALB/c-Rag2-/-gammac-/-mice. J Virol 81: 2700-2712.
18. Bartlett, DW and Davis, ME (2006). Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging. Nucleic Acids Res 34: 322-333.
19. Song, E, Lee, SK, Dykxhoorn, DM, Novina, C, Zhang, D, Crawford, K, et al. (2003). Sustained small interfering RNA-mediated human immunodefciency virus type 1 inhibition in primary macrophages. J Virol 77: 7174-7181.
20. Manjunath, N, Kumar, P, Lee, SK and Shankar, P (2006). Interfering antiviral immunity: application, subversion, hope? Trends Immunol 27: 328-335.
21. An, DS, Donahue, RE, Kamata, M, Poon, B, Metzger, M, Mao, SH, et al. (2007). Stable reduction of CCR5 by RNAi through hematopoietic stem cell transplant in non-human primates. Proc Natl Acad Sci USA 104: 13110-13115.
22. Lu, C, Shimaoka, M, Salas, A and Springer, TA (2004). The binding sites for competitive antagonistic, allosteric antagonistic, and agonistic antibodies to the I domain of integrin LFA-1. J Immunol 173: 3972-3978.
23. Giguère, JF and Tremblay, MJ (2004). Statin compounds reduce human immunodefciency virus type 1 replication by preventing the interaction between virion-associated host intercellular adhesion molecule 1 and its natural cell surface ligand LFA-1. J Virol 78: 12062-12065.
24. Hioe, CE, Chien, PC Jr, Lu, C, Springer, TA, Wang, XH, Bandres, J, et al. (2001). LFA-1 expression on target cells promotes human immunodefciency virus type 1 infection and transmission. J Virol 75: 1077-1082.
25. Sun, X, Rogoff, HA and Li, CJ (2008). Asymmetric RNA duplexes mediate RNA interference in mammalian cells. Nat Biotechnol 26: 1379-1382.
26. Schwarz, DS, Hutvágner, G, Du, T, Xu, Z, Aronin, N and Zamore, PD (2003). Asymmetry in the assembly of the RNAi enzyme complex. Cell 115: 199-208.
27. Kumar, P, Wu, H, McBride, JL, Jung, KE, Kim, MH, Davidson, BL, et al. (2007). Transvascular delivery of small interfering RNA to the central nervous system. Nature 448: 39-43.
28. Peer, D and Margalit, R (2000). Physicochemical evaluation of a stability-driven approach to drug entrapment in regular and in surface-modifed liposomes. Arch Biochem Biophys 383: 185-190.
29. Peer, D, Florentin, A and Margalit, R (2003). Hyaluronan is a key component in cryoprotection and formulation of targeted unilamellar liposomes. Biochim Biophys Acta 1612: 76-82.
30. Lan, P, Tonomura, N, Shimizu, A, Wang, S and Yang, YG (2006). Reconstitution of a functional human immune system in immunodefcient mice through combined human fetal thymus/liver and CD34+ cell transplantation. Blood 108: 487-492.
31. Wu, H, Neilson, JR, Kumar, P, Manocha, M, Shankar, P, Sharp, PA, et al. (2007). miRNA profling of naïve, effector and memory CD8 T cells. PLoS ONE 2: e1020.